We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
+14.76%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.1B
AUM Growth
+$4.5M
Cap. Flow
-$179M
Cap. Flow %
-8.52%
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
83
Reduced
267
Closed
35

Top Sells

Rank Stock Value
1
BEKE icon
KE Holdings
BEKE
+$70.4M
2
FUTU icon
Futu Holdings
FUTU
+$30.9M
3
AAPL icon
Apple
AAPL
+$18.5M
4
MSFT icon
Microsoft
MSFT
+$11.9M
5
AMAT icon
Applied Materials
AMAT
+$9.76M

Sector Composition

Rank Sector Weight
1 Technology 43.87%
2 Consumer Discretionary 23.94%
3 Communication Services 11.36%
4 Healthcare 5.11%
5 Financials 3.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NKE icon
351
Nike
NKE
$61.9B
$217K 0.01%
+3,061
New +$184K
MIRM icon
352
Mirum Pharmaceuticals
MIRM
$6.89B
$211K 0.01%
4,143
-704
-15% -$31.3K
AJG icon
353
Arthur J. Gallagher & Co
AJG
$63.7B
$209K 0.01%
654
-149
-19% -$49.1K
MSCI icon
354
MSCI
MSCI
$40B
$209K 0.01%
363
-2,739
-88% -$1.52M
MMM icon
355
3M
MMM
$89B
$208K 0.01%
1,367
+2
+0.1% +$286
WM icon
356
Waste Management
WM
$95.9B
$206K 0.01%
900
-22
-2% -$5.1K
CYD icon
357
China Yuchai International
CYD
$1.69B
$206K 0.01%
+8,613
New +$151K
SHW icon
358
Sherwin-Williams
SHW
$78.3B
$204K 0.01%
595
-121
-17% -$41.9K
APGE icon
359
Apogee Therapeutics
APGE
$10.2B
$204K 0.01%
+4,700
New +$179K
TVTX icon
360
Travere Therapeutics
TVTX
$5.33B
$204K 0.01%
13,789
+236
+2% +$3.91K
EQIX icon
361
Equinix
EQIX
$107B
$202K 0.01%
254
-456
-64% -$387K
RXRX icon
362
Recursion Pharmaceuticals
RXRX
$1.57B
$201K 0.01%
39,653
-16,272
-29% -$79.9K
DNLI icon
363
Denali Therapeutics
DNLI
$3.67B
$190K 0.01%
13,612
+1,543
+13% +$21.7K
BHVN icon
364
Biohaven
BHVN
$2.16B
$190K 0.01%
13,492
+2,307
+21% +$41.1K
IMVT icon
365
Immunovant
IMVT
$8.09B
$190K 0.01%
11,854
-1,121
-9% -$17K
DVAX
366
DELISTED
Dynavax Technologies
DVAX
$180K 0.01%
18,113
+2,752
+18% +$29K
NVAX icon
367
Novavax
NVAX
$1.23B
$178K 0.01%
28,280
+2,326
+9% +$15.4K
ARDX icon
368
Ardelyx
ARDX
$1.24B
$157K 0.01%
40,023
+3,255
+9% +$13.4K
NTLA icon
369
Intellia Therapeutics
NTLA
$1.5B
$135K 0.01%
14,339
-2,492
-15% -$20.5K
ETNB
370
DELISTED
89bio
ETNB
$134K 0.01%
13,622
+795
+6% +$6.58K
SNDX icon
371
Syndax Pharmaceuticals
SNDX
$1.84B
$131K 0.01%
14,033
-1,998
-12% -$22K
GERN icon
372
Geron
GERN
$911M
$130K 0.01%
92,238
+9,849
+12% +$14K
DYN icon
373
Dyne Therapeutics
DYN
$4.04B
$117K 0.01%
12,274
-1,497
-11% -$16.5K
F icon
374
Ford
F
$57.3B
$111K 0.01%
10,208
AKBA icon
375
Akebia Therapeutics
AKBA
$327M
$103K ﹤0.01%
28,273
+8,962
+46% +$24.6K

Similar funds

E Fund Management's Q2 2025 Portfolio in Review

As of Q2 2025, E Fund Management held 429 positions worth $2.1B, up 0.21% from $2.09B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

E Fund Management withdrew a net $179M in Q2 2025, closing 35 positions and reducing 267 holdings. Its most notable exit was KE Holdings, an estimated $70.4M position sold in full.

By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, E Fund Management opened a new position in Invesco DB Oil Fund worth $11M.

  • E Fund Management's largest Q2 2025 buy was Invesco DB Oil Fund: 835,473 shares worth $11M.
  • E Fund Management added most to abrdn Physical Gold Shares ETF in Q2 2025, an estimated $19.9M increase.
  • E Fund Management's biggest Q2 2025 reduction was Futu Holdings, cutting an estimated $30.9M.
  • E Fund Management fully exited KE Holdings in Q2 2025, selling an estimated $70.4M.
  • E Fund Management's ten largest holdings make up 52% of its $2.1B portfolio in Q2 2025.
  • E Fund Management opened 31 new positions and closed 35 in Q2 2025.
  • E Fund Management's portfolio value rose 0.21% quarter-over-quarter to $2.1B.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.